Trials / Completed
CompletedNCT00418002
Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.
A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 60 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess safety and tolerability of AQW051 administered in single and multiple doses to elderly healthy volunteers. In addition, pharmacokinetic effects will be assessed and the possible effects on cognition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AQW051 |
Timeline
- Start date
- 2006-05-01
- First posted
- 2007-01-04
- Last updated
- 2007-06-22
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00418002. Inclusion in this directory is not an endorsement.